ClinicalTrials.gg
CompletedNCT00620542SATURNUpdated Jul 16, 2012Results posted

CRESTOR Athero Imaging Head to Head IVUS Study

A Phase 3 interventional study of Rosuvastatin and Atorvastatin in Coronary Atherosclerosis, sponsored by AstraZeneca. Completed at 195 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-07-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,333
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Enrollment
Largest of 34
2,333 · median 175
Started
2008
the only one that year
Phase 3
7 of 34
1 open now
Registered
2nd of 34
by date
Lead sponsor
4 of 34
AstraZeneca

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one has the largest enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 2nd registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease.

03

Conditions studied

  • Coronary Atherosclerosis

Keywords

  • Coronary artery disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical indication for coronary angiography
  • Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has >20% reduction in lumen diameter by visual estimation
  • Left main coronary artery must have \<=50% reduction in lumen diameter by visual estimation
  • LDL-C >100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C >80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.
  • Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).
  • heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,333 participants (actual)

Study arms

  • Experimental
    Rosuvastatin 20 mg

    Rosuvastatin 20 mg distributed in 2-week run-in period

    Drug: Rosuvastatin

  • Active comparator
    Atorvastatin 40 mg

    Atorvastatin 40 mg distributed in 2-week run-in period

    Drug: Atorvastatin

  • Experimental
    Rosuvastatin 40 mg

    Rosuvastatin 40 mg distributed in core 2-year study

    Drug: Rosuvastatin

  • Active comparator
    Atorvastatin 80 mg

    Atorvastatin 80 mg distributed in core 2-year study

    Drug: Atorvastatin

Interventions

  • capsule, oral, once daily

    Also known as: Crestor

  • capsule, oral, one daily

    Also known as: Lipitor

06

What researchers measure

Primary outcomes

  1. Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)

    Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: \[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.

    Time frame: End of study (Week 104)

Secondary outcomes

  1. Numbers of Patients Showing Regression in PAV

    Regression defined as a change from baseline in PAV \< 0

    Time frame: End of study (Week 104)

  2. Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)

    Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.

    Time frame: End of study (Week 104)

  3. Numbers of Patients Showing Regression in TAV

    Regression defined as a change from baseline in TAV \< 0

    Time frame: End of study (Week 104)

  4. Total Cholesterol Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  5. LDL-C Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  6. HDL-C Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  7. Triglycerides Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  8. Non-HDL-C Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  9. LDL-C/HDL-C Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  10. Total Cholesterol/HDL-C Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  11. Non-HDL-C/HDL-C Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  12. Apolipoprotein B Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  13. Apolipoprotein A-1 Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  14. Apoliprotein B/Apolipoprotein A-1 Blood Level

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

  15. VLDL-C During the 104 Week Treatment Period

    Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

    Time frame: 104 weeks

07

Results

Posted Jun 25, 2012

Participant flow

2333 Coronary Artery Disease (CAD) patients with clinical indication for coronary angiography were randomized to Part A, the 2-week run-in period. Of these, 1578 patients were treated and 1385 completed Part A. The 1385 patients completing Part A were then randomized to Part B the core study period of 104 weeks of treatment.

Part A (Run-in - 2 Weeks)
Participant flow — Part A (Run-in - 2 Weeks)
MilestoneRosuvastatin 20 mgAtorvastatin 40 mgRosuvastatin 40 mgAtorvastatin 80 mg
Started1167116600
Received treatment78379500
Completed69569000
Not completed47247600
Withdrew: Adverse event121500
Withdrew: Protocol violation40640900
Withdrew: Withdrawal by subject434000
Withdrew: Lost to follow-up7600
Withdrew: Protocol violation0100
Withdrew: Safety reasons0100
Withdrew: Ivus not available4400
Part B (2 Year Core Study)
Participant flow — Part B (2 Year Core Study)
MilestoneRosuvastatin 20 mgAtorvastatin 40 mgRosuvastatin 40 mgAtorvastatin 80 mg
Started00694691
Received treatment00691689
Intent-to-treat population00520519
Completed00546547
Not completed00148144
Withdrew: Adverse event004649
Withdrew: Protocol violation0035
Withdrew: Withdrawal by subject005554
Withdrew: Lost to follow-up00209
Withdrew: Protocol violation001316
Withdrew: Safety reasons0023
Withdrew: Study specific discontinuation criteris0066
Withdrew: Ivus not available0032

Outcome measures

PrimaryChange From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)

Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as: \[sum(EEMcsa-LUMENcsa)/sum EEMcsa\]\*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.

Time frame:
End of study (Week 104)
Reported as:
Median · Percent change
Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)
Percent changeRosuvastatin 40 mgAtorvastatin 80 mg
Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)-1.22 (-1.52 to -0.90)-0.99 (-1.19 to -0.63)
SecondaryNumbers of Patients Showing Regression in PAV

Regression defined as a change from baseline in PAV \< 0

Time frame:
End of study (Week 104)
Reported as:
Number · Participants
Numbers of Patients Showing Regression in PAV
ParticipantsRosuvastatin 40 mgAtorvastatin 80 mg
Numbers of Patients Showing Regression in PAV356328
SecondaryChange From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)

Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.

Time frame:
End of study (Week 104)
Reported as:
Median · mm^3
Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)
mm^3Rosuvastatin 40 mgAtorvastatin 80 mg
Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)-6.39 (-7.52 to -5.12)-4.42 (-5.98 to -3.26)
SecondaryNumbers of Patients Showing Regression in TAV

Regression defined as a change from baseline in TAV \< 0

Time frame:
End of study (Week 104)
Reported as:
Number · Participants
Numbers of Patients Showing Regression in TAV
ParticipantsRosuvastatin 40 mgAtorvastatin 80 mg
Numbers of Patients Showing Regression in TAV371336
SecondaryTotal Cholesterol Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
Total Cholesterol Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
Total Cholesterol Blood Level139.38 ± 1.24144.05 ± 1.23
SecondaryLDL-C Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
LDL-C Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
LDL-C Blood Level62.64 ± 1.0070.18 ± 0.99
SecondaryHDL-C Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
HDL-C Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
HDL-C Blood Level50.43 ± 0.5448.64 ± 0.53
SecondaryTriglycerides Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
Triglycerides Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
Triglycerides Blood Level132.50 ± 2.44126.58 ± 2.43
SecondaryNon-HDL-C Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
Non-HDL-C Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
Non-HDL-C Blood Level88.95 ± 1.1595.41 ± 1.14
SecondaryLDL-C/HDL-C Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · Ratio
LDL-C/HDL-C Blood Level
RatioRosuvastatin 40 mgAtorvastatin 80 mg
LDL-C/HDL-C Blood Level1.30 ± 0.021.50 ± 0.02
SecondaryTotal Cholesterol/HDL-C Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · Ratio
Total Cholesterol/HDL-C Blood Level
RatioRosuvastatin 40 mgAtorvastatin 80 mg
Total Cholesterol/HDL-C Blood Level2.88 ± 0.033.08 ± 0.03
SecondaryNon-HDL-C/HDL-C Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · Ratio
Non-HDL-C/HDL-C Blood Level
RatioRosuvastatin 40 mgAtorvastatin 80 mg
Non-HDL-C/HDL-C Blood Level1.88 ± 0.032.08 ± 0.03
SecondaryApolipoprotein B Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
Apolipoprotein B Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
Apolipoprotein B Blood Level72.55 ± 0.8575.12 ± 0.85
SecondaryApolipoprotein A-1 Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
Apolipoprotein A-1 Blood Level
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
Apolipoprotein A-1 Blood Level146.81 ± 1.03137.68 ± 1.02
SecondaryApoliprotein B/Apolipoprotein A-1 Blood Level

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · Ratio
Apoliprotein B/Apolipoprotein A-1 Blood Level
RatioRosuvastatin 40 mgAtorvastatin 80 mg
Apoliprotein B/Apolipoprotein A-1 Blood Level0.51 ± 0.010.56 ± 0.01
SecondaryVLDL-C During the 104 Week Treatment Period

Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.

Time frame:
104 weeks
Reported as:
Least squares mean · mg/dL
VLDL-C During the 104 Week Treatment Period
mg/dLRosuvastatin 40 mgAtorvastatin 80 mg
VLDL-C During the 104 Week Treatment Period26.05 ± 0.4525.03 ± 0.44

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 20 mg—21/783 (2.7%)0/783 (0%)
Atorvastatin 40 mg—25/795 (3.1%)0/795 (0%)
Rosuvastatin 40 mg—194/691 (28.1%)210/691 (30.4%)
Atorvastatin 80 mg—168/689 (24.4%)213/689 (30.9%)
Most frequent serious events
Showing 10 of 224
Most frequent serious events
EventRosuvastatin 20 mgAtorvastatin 40 mgRosuvastatin 40 mgAtorvastatin 80 mg
Angina PectorisCardiac disorders5/7835/79525/69128/689
Angina UnstableCardiac disorders0/7832/79517/69111/689
Non-Cardiac Chest PainGeneral disorders1/7833/79514/6917/689
Coronary Artery StenosisCardiac disorders1/7830/79512/6919/689
Coronary Artery DiseaseCardiac disorders0/7830/79510/6914/689
Chest PainGeneral disorders0/7830/7957/6917/689
Acute Myocardial InfarctionCardiac disorders0/7831/7955/6916/689
Atrial FibrillationCardiac disorders0/7831/7953/6916/689
SyncopeNervous system disorders0/7830/7953/6916/689
In-Stent Coronary Artery RestenosisInjury, poisoning and procedural complications0/7830/7956/6913/689
Most frequent other events
Most frequent other events
EventRosuvastatin 20 mgAtorvastatin 40 mgRosuvastatin 40 mgAtorvastatin 80 mg
MYALGIAMusculoskeletal and connective tissue disorders0/7830/79599/69191/689
ANGINA PECTORISCardiac disorders0/7830/79561/69165/689
ARTHRALGIAMusculoskeletal and connective tissue disorders0/7830/79550/69143/689
HYPERTENSIONVascular disorders0/7830/79536/69140/689
FATIGUEGeneral disorders0/7830/79532/69139/689

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rosuvastatin 40 mgAtorvastatin 80 mgTotal
<=18 years000
Between 18 and 65 years402395797
>=65 years118124242
Age Continuous
Age Continuous(years)Rosuvastatin 40 mgAtorvastatin 80 mgTotal
Age (yrs) at Week 057.4 ± 8.6057.9 ± 8.5057.6 ± 8.55
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 40 mgAtorvastatin 80 mgTotal
Female141133274
Male379386765
08

Study locations

195 sites
  • Research Site
    Huntsville, Alabama, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Mountain View, California, United States
  • Research Site
    Sacramento, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Santa Rosa, California, United States
  • Research Site
    Torrance, California, United States
  • Research Site
    Boulder, Colorado, United States
  • Research Site
    Greeley, Colorado, United States
  • Research Site
    Loveland, Colorado, United States
  • Research Site
    Farmington, Connecticut, United States
  • Research Site
    Washington, District of Columbia, United States
  • Research Site
    Clearwater, Florida, United States
  • Research Site
    Ft Lauderdale, Florida, United States
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Melbourne, Florida, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    Tampa, Florida, United States
  • Research Site
    Winter Haven, Florida, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Augusta, Georgia, United States
  • Research Site
    Elkhart, Indiana, United States
  • Research Site
    Hammond, Indiana, United States
  • Research Site
    Indianapolis, Indiana, United States
  • Research Site
    Merrillville, Indiana, United States
  • Research Site
    Valparaiso, Indiana, United States
  • Research Site
    Davenport, Iowa, United States
  • Research Site
    Iowa City, Iowa, United States
  • Research Site
    West Des Moines, Iowa, United States
  • Research Site
    Ashland, Kentucky, United States
  • Research Site
    Lexington, Kentucky, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Covington, Louisiana, United States
  • Research Site
    Bethesda, Maryland, United States
  • Research Site
    Columbia, Maryland, United States
  • Research Site
    Takoma Park, Maryland, United States
  • Research Site
    Bay City, Michigan, United States
  • Research Site
    Grand Blanc, Michigan, United States
  • Research Site
    Kalamazoo, Michigan, United States
  • Research Site
    Midland, Michigan, United States
  • Research Site
    Muskegon, Michigan, United States
  • Research Site
    Petoskey, Michigan, United States
  • Research Site
    Saginaw, Michigan, United States
  • Research Site
    Southfield, Michigan, United States
  • Research Site
    Duluth, Minnesota, United States
  • Research Site
    Minneapolis, Minnesota, United States
  • Research Site
    Rochester, Minnesota, United States
  • Research Site
    St Cloud, Minnesota, United States
  • Research Site
    St. Paul, Minnesota, United States
  • Research Site
    Columbia, Missouri, United States
  • Research Site
    Kansas City, Missouri, United States
  • Research Site
    Missoula, Montana, United States
  • Research Site
    Lincoln, Nebraska, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    New Brunswick, New Jersey, United States
  • Research Site
    Ridgewood, New Jersey, United States
  • Research Site
    Albuquerque, New Mexico, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Johnson City, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Roslyn, New York, United States
  • Research Site
    Williamsville, New York, United States
  • Research Site
    Charlotte, North Carolina, United States
  • Research Site
    Gastonia, North Carolina, United States
  • Research Site
    Greensboro, North Carolina, United States
  • Research Site
    Fargo, North Dakota, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Cleveland, Ohio, United States
  • Research Site
    Columbus, Ohio, United States
  • Research Site
    Elyria, Ohio, United States
  • Research Site
    Kettering, Ohio, United States
  • Research Site
    Middleburg Heights, Ohio, United States
  • Research Site
    Perrysburg, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Tulsa, Oklahoma, United States
  • Research Site
    Bend, Oregon, United States
  • Research Site
    Eugene, Oregon, United States
  • Research Site
    Hillsboro, Oregon, United States
  • Research Site
    Danville, Pennsylvania, United States
  • Research Site
    Doylestown, Pennsylvania, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Wormleysburg, Pennsylvania, United States
  • Research Site
    Charleston, South Carolina, United States
  • Research Site
    Chattanooga, Tennessee, United States
  • Research Site
    Germantown, Tennessee, United States
  • Research Site
    Knoxville, Tennessee, United States
  • Research Site
    Memphis, Tennessee, United States
  • Research Site
    Oak Ridge, Tennessee, United States
  • Research Site
    Dallas, Texas, United States
  • Research Site
    San Antonio, Texas, United States
  • Research Site
    Charlottesville, Virginia, United States
  • Research Site
    Bellevue, Washington, United States
  • Research Site
    Spokane, Washington, United States
  • Research Site
    Tacoma, Washington, United States
  • Research Site
    Cap. Fed., Buenos Aires, Argentina
  • Research Site
    Ciudad de Buenos Aires, Buenos Aires, Argentina
  • Research Site
    Rosario, Santa Fe-argentina, Argentina

Showing the first 100 of 195 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014 Oct;7(10):1013-22. doi: 10.1016/j.jcmg.2014.04.019. Epub 2014 Sep 17. PubMed 25240453 ↗
  • Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr;15(4):380-8. doi: 10.1093/ehjci/jet251. Epub 2014 Jan 20. PubMed 24448227 ↗
  • Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013 Nov 26;128(22):2395-403. doi: 10.1161/CIRCULATIONAHA.113.004243. Epub 2013 Sep 16. PubMed 24043299 ↗
  • Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15. PubMed 22085316 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2008
First posted
Feb 21, 2008
Start
Jan 2008
Primary completionActual
Jun 2011
CompletionActual
Jun 2011
Results first posted
Jun 25, 2012
Last update
Jul 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00620542
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 21, 2008
Start date
Jan 2008
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jun 25, 2012
Last update
Jul 16, 2012

Study contacts

Stephen J Nicholls, MBBS, PhD
principal investigator · Cleveland Clinic Foundation, Cardiovascular Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion